Detection of <i>BCR-ABL</i> Mutations and Resistance to Imatinib Mesylate

Implications of imatinib mesylate for hematopoietic stem cell transplantation

Seminars in Hematology ◽

10.1053/shem.2001.27081 ◽

2001 ◽

Vol 38 (3, Suppl 8) ◽

pp. 28-34 ◽

Cited By ~ 1

Author(s):

John Goldman

Keyword(s):

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Imatinib Mesylate ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Hematopoietic Stem

Download Full-text

Initial experiences utilizing perfusion CT in the follow-up of patients with gastrointestinal stromal tumors under imatinib mesylate treatment

RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren ◽

10.1055/s-0028-1085909 ◽

2008 ◽

Vol 180 (09) ◽

Author(s):

F Berger ◽

M Hittinger ◽

M Schlemmer ◽

T Saam ◽

K Nikolaou ◽

...

Keyword(s):

Imatinib Mesylate ◽

Gastrointestinal Stromal Tumors ◽

Perfusion Ct ◽

Stromal Tumors

Download Full-text

Therapeutic interest of Imatinib Mesylate in osteosarcoma

Bone Abstracts ◽

10.1530/boneabs.1.pp141 ◽

2013 ◽

Author(s):

Berengere Gobin ◽

Gatien Moriceau ◽

Benjamin Ory ◽

Regis Brion ◽

Francoise Redini ◽

...

Keyword(s):

Imatinib Mesylate

Download Full-text

Faculty Opinions recommendation of Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1033567.489987 ◽

2006 ◽

Author(s):

Gerhard Ehninger

Keyword(s):

Imatinib Mesylate ◽

Therapeutic Agent

Download Full-text

Faculty Opinions recommendation of Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1033567.388749 ◽

2006 ◽

Author(s):

John Kyriakis

Keyword(s):

Imatinib Mesylate ◽

Therapeutic Agent

Download Full-text

Faculty Opinions recommendation of Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1105194.561388 ◽

2008 ◽

Author(s):

Michael Deininger ◽

Paul La Rosée

Keyword(s):

Chronic Myeloid Leukemia ◽

Imatinib Mesylate ◽

Interferon Alpha ◽

Myeloid Leukemia ◽

Chronic Phase ◽

Long Term Follow Up ◽

Interferon Alpha Treatment

Download Full-text

Epigenetic Silencing and Resistance to Imatinib Mesylate in CML

10.21236/ada447574 ◽

2005 ◽

Author(s):

Jean-Pierre Issa

Keyword(s):

Imatinib Mesylate ◽

Epigenetic Silencing

Download Full-text

Combinations of Novel Histone Deacetylase and Bcr-Abl Inhibitors in the Therapy of Imatinib Mesylate-Sensitive and Refractory Bcr-Abl Expressing Leukemia

10.21236/ada484223 ◽

2007 ◽

Author(s):

Kapil Bhalla

Keyword(s):

Imatinib Mesylate ◽

Histone Deacetylase

Download Full-text

Cucurbitacin B Enhances the Anticancer Effect of Imatinib Mesylate Through Inhibition of MMP-2 Expression in MCF-7 and SW480 Tumor Cell Lines

Anti-Cancer Agents in Medicinal Chemistry ◽

10.2174/1871520616666160211124038 ◽

2016 ◽

Vol 16 (6) ◽

pp. 747-754 ◽

Cited By ~ 7

Author(s):

Filiz Bakar

Keyword(s):

Tumor Cell ◽

Imatinib Mesylate ◽

Cell Lines ◽

Tumor Cell Lines ◽

Anticancer Effect ◽

Cucurbitacin B ◽

Mcf 7

Download Full-text

Optical, Structural and Thermodynamic Studies of the Association of an Anti-leucamic Drug Imatinib Mesylate with Transport Protein

Journal of Fluorescence ◽

10.1007/s10895-011-0986-0 ◽

2011 ◽

Vol 22 (1) ◽

pp. 521-528 ◽

Cited By ~ 13

Author(s):

Ashwini H. Hegde ◽

Reeta Punith ◽

J. Seetharamappa

Keyword(s):

Imatinib Mesylate ◽

Transport Protein ◽

Thermodynamic Studies

Download Full-text

Detection of BCR-ABL Mutations and Resistance to Imatinib Mesylate

Implications of imatinib mesylate for hematopoietic stem cell transplantation

Initial experiences utilizing perfusion CT in the follow-up of patients with gastrointestinal stromal tumors under imatinib mesylate treatment

Therapeutic interest of Imatinib Mesylate in osteosarcoma

Faculty Opinions recommendation of Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Faculty Opinions recommendation of Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Faculty Opinions recommendation of Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.

Epigenetic Silencing and Resistance to Imatinib Mesylate in CML

Combinations of Novel Histone Deacetylase and Bcr-Abl Inhibitors in the Therapy of Imatinib Mesylate-Sensitive and Refractory Bcr-Abl Expressing Leukemia

Cucurbitacin B Enhances the Anticancer Effect of Imatinib Mesylate Through Inhibition of MMP-2 Expression in MCF-7 and SW480 Tumor Cell Lines

Optical, Structural and Thermodynamic Studies of the Association of an Anti-leucamic Drug Imatinib Mesylate with Transport Protein

Export Citation Format